Introduction
============

The objective of current research activity on RA-associated autoimmune systems is to find a disease-specific marker \[[@B1]\]. It would be simplistic to view that marker as being primarily of importance in clinical diagnosis. Indeed, its net diagnostic contribution beyond that of using the American College of Rheumatology (ACR) criteria with rheumatoid factor is likely to be clinically insignificant in established RA \[[@B2],[@B3],[@B4]\]. What clinicians really need is a marker that would be a good a priori predictor of future disease severity \[[@B5]\]. In contrast, what researchers are looking for are fresh etiopathogenic clues \[[@B6]\].

Sa for the clinician
====================

The serum of Mrs Sa\... identifies unique tissue-specific banding patterns at approximately 50 kDa in western blots with normal human spleen and placenta, and rheumatoid synovial extracts \[[@B7],[@B8],[@B9]\]. Until recently (see below), the Sa polypeptides were not found in extracts of a variety of cells of different lineage and were different in western blots from all previously described systems associated with RA including rheumatoid factor, filaggrin and calpastatin \[[@B7],[@B9],[@B10]\]. The components of the Sa system are present at high concentrations in the rheumatoid joint: antigen in the synovium and IgG antibody in the fluid \[[@B8],[@B11]\]. Looking for autoantibodies in sera of 20 pairs of monozygotic twins discordant for RA, anti-Sa antibodies were found only in rheumatoid twins, whereas all the previously mentioned autoantibodies could be found in both rheumatoid and healthy twins \[[@B12]\]. A caveat to that study is the fact that we could test only those sera with the immunofluorescence method for anti-perinuclear factor (APF) and anti-keratin antibodies (AKA). Both tests are plagued with problems of subjective interpretation. The possibility therefore cannot be excluded that our observation could be extended to antibodies against other citrullinated protein or peptide antigens if properly assayed (see below). Overall, those results suggest a closer association of anti-Sa with the disease than with the genes \[[@B12]\]. That last piece of information supports the hypothesis of an environmental trigger.

To submit patients to early aggressive therapy, candidate markers are needed that are both present at disease onset and predictive of disease severity. The shared epitopes of human leucocyte antigen (HLA)-DR alleles have provided epidemiological insight in our understanding of RA but have proved to be of little utility in the clinic because shared epitope genotyping is essentially an a posteriori marker of disease severity \[[@B3],[@B13],[@B14],[@B15]\]. In contrast, the anti-Sa antibody is present in early disease \[[@B4],[@B7],[@B16]\] and seems to be slightly better than HLA genotyping and other autoantibodies as a predictor of \`erosivity\' \[[@B3],[@B4]\]. The anti-Sa antibody sensitivity (approximately 43%), specificity (approximately 99%) and positive predictive value (approximately 97%) for RA have been remarkably reproducible in more than 3000 patients from Europe, America and Asia \[[@B3],[@B4],[@B7],[@B16],[@B17],[@B18]\] (Table [1](#T1){ref-type="table"}).

Sa for the researcher
=====================

In the past 10 years we have purified Sa from human placenta and obtained several amino acid microsequences that all pointed to vimentin as the elusive Sa antigen \[[@B15],[@B17]\]. That was in flagrant contradiction of all the published work on anti-vimentin autoantibodies in human diseases and with the observed RA specificity. All our efforts at cloning Sa with affinity-purified and IgG-adsorbed rheumatoid anti-Sa antibodies to immunoscreen human placental cDNA expression libraries were unsuccessful. As a by-product, we cloned the RA-associated autoantigen, calpastatin (see below) \[[@B16]\]. We were even unable to clone vimentin. We were obviously missing something. Interestingly, the Sa and citrulline-related autoimmune systems (anti-perinuclear-APF, anti-profilaggrin-APF, anti-keratin-AKA, anti-filaggrin-AFA and anti-citrullinated peptides-ACP antibodies) have the same high specificity for RA and early predictive potential for severe RA \[[@B3],[@B4],[@B19],[@B20],[@B21]\]. The explanatory breakthrough came from the recent research on filaggrin.

Sa and filaggrin are two different proteins that are both specifically and often (but not always) simultaneously targeted by the same RA sera \[[@B3]\]. A survey of the metabolic handling of filaggrin reveals that it is dephosphorylated, deiminated and twice proteolytically cleaved by enzymes, the latter step being by means of the calcium-dependent cytosolic calpains \[[@B1],[@B22],[@B23],[@B24],[@B25]\]. The identification of the citrulline epitopes responsible for the reactivity of RA sera with filaggrin was therefore a logical and major step forward \[[@B19],[@B20]\]. The epitopes are centered on citrulline residues resulting from the deimination of selected arginine residues on filaggrin. That post-translational modification is performed by the calcium-dependent peptidylarginine deiminase (PAD) present in the skin. There are at least four other PAD isoenzymes in other tissues (data from GenBank). We recently identified by western blot an Sa-related, disease-specific, complex banding pattern in ECV304, a human endothelial cell line, and in human umbilical-vein endothelial cells. Exactly the same multiplicity of the reaction was seen with a rabbit polyclonal anti-citrulline antibody \[[@B26]\]. We extended that observation to show that bovine albumin, total histones and myelin basic protein could all serve as a carrier of the RA-specific epitopes when they were citrullinated *in vitro* with PAD \[[@B27]\]. We have since cloned vimentin by PCR and citrullinated its expressed recombinant *in vitro*. By differential absorption it proved to be the Sa antigen (Lapointe E, Rochdi MD, Ménard HA, in preparation). Trichohyalin (APF), filaggrin (AFA), keratin (AKA), vimentin (anti-Sa), myelin basic protein and fibrin \[[@B28]\] are all citrullinated *in vivo*. All those proteins can also be citrullinated *in vitro* and function as RA-specific targets, albeit with different sensitivity. The clinical and pathophysiological significance of that phenomenon does not seem to be important *in vivo*, at least in the skin or nervous system in RA. It might be important if the carrier-hapten is generated and accessible to the adaptive immune system in the articular tissues.

Future research on Sa
=====================

Our working hypothesis is that Sa or citrullinated vimentin is the original hapten-carrier immunogen. Classically, antigen-presenting cells will process the original carrier and present its derived peptide in an MHC-restricted fashion at the T cell level and carrier-specific help will then be provided to the hapten-specific B cell. Although the original carrier is important *in vivo*, the carrier is not important in detecting anti-hapten antibodies *in vitro*. That explains why apparently entirely different RA-specific humoral systems were found independently. Many questions now arise, of which the following are a sample. How does citrullination of specific arginine residues come about? Are there cell-specific PADs? How many different PADs are there in each cell type? Vimentin is preferentially citrullinated during apoptosis; that results in protein denaturation and the disorganization of intermediate filaments \[[@B29],[@B30]\]. However, although vimentin is untouched, Sa or citrullinated vimentin is destroyed almost immediately *in vitro* by calpains \[[@B17]\]. Why can it survive as a molecule only in certain cells such as endothelial cells? Where else can it survive? Is that related to its immunogenicity and why? Why is vimentin not co-targeted more often in RA? Is the RA-associated secondary development of antibodies against calpastatin, the natural inhibitor of calpains, a related defence mechanism or a pro-inflammatory amplification loop \[[@B31]\]? Is the extraordinary fine disease specificity of the autoantibodies representing the mythical footprint of the elusive initial causative event(s)? Indeed, several microorganisms have arginine-to-citrulline deiminase activities. Can they also citrullinate proteins? Such a post-translational modification coming from the environment would be a fresh illustration of the \`hit-and-run\' theory of autoimmunity.

In autoimmune diseases, \`multifactorial\' and \`polygenic\' are vogue words. \`Multifactorial\' could mean the assault of non-specific environmental factors acting preferentially on specific cells or tissues. That would result in the overproduction of specific endogenous or exogenous arginine deiminases with the over-citrullination or under-citrullination of residues normally or not normally modified by that post-translational pathway. Because citrullination, whether by means of apoptosis or by some other mechanism, is a natural phenomenon, those neo-antigens would need to occur in individuals with the appropriate polygenic background (30 or so genes, as in lupus) that would modulate apoptosis, break tolerance, mount the specific immune response and influence disease expression. Exploring that framework will probably earn great dividends for both patients and science.

###### 

Diagnostic significance of anti-Sa in the rheumatic diseases

                         Total no.   Rheumatoid              Positive predictive
  --------- ------------ ----------- ------------ ---- ----- ---------------------
  Canada    \[[@B7]\]    482         206          43   99    97
  Spain     \[[@B17]\]   1087        360          33   100   99
  France    \[[@B3]\]    403         154          40   92    n/a
  Austria   \[[@B16]\]   247         46           37   98    n/a
  China     \[[@B18]\]   518         191          32   99    94
  Total                  2737        957          37   98    97

The control populations were normal individuals and patients with degenerative arthritis from the communities shown, autoimmune patients with systemic lupus erythematosus, Sjögren and other systemic connective tissue diseases, and patients with chronic arthritis of the spondylarthropathy variants. All RA patients satisfied the ACR criteria, including those with early (less than 1 year) disease. It is important to note that the data on sensitivity, specificity and positive predictive value for RA are valid only for established RA cohorts and would not necessarily apply to early synovitis cohorts, where satisfying the ACR criteria for RA at entry is not a prerequisite. n/a, not applicable.
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